ASX ANNOUNCEMENT

30 October 2024

Webinar recording with CEO Paul Long *Now available*

Little Green Pharma Ltd (ASX: LGP, "**LGP**" or "the **Company**") advises that a recording of the recent shareholder webinar with CEO Paul Long, discussing the Company's September quarter activities and performance, is now available for viewing.

In the webinar, CEO Paul Long provides a comprehensive overview of a record-breaking quarter for LGP, with highlights including a revenue increase to \$10.2 million (unaudited) (up 40% on the previous quarter), an uptick in product distribution, and cash flow positivity achievements.

Paul details the Company's strategic growth initiatives, including expansions into the German, UK, Polish and French markets, where increased demand and early-stage regulatory changes present promising opportunities.

Paul also discusses LGP's growing product portfolio, which now spans 26 products across three facilities in Perth, Busselton, and Denmark, with a combined cannabis production capacity of 30 tonnes. Additionally, he elaborates on recent cost-saving measures and partnerships, such as LGP's agreement with HIF to support its Reset Mind Sciences division, underscoring the Company's focus on delivering innovative treatments.

The recorded webinar is available for shareholders and interested parties under the Company's Investor Centre website <u>https://investlittlegreenpharma.com/</u> or via this link: <u>https://youtu.be/vE0tpPU1MG0</u>



ENDS APPROVED FOR RELEASE

Alistair Warren Company Secretary

For further information please contact:

Alistair Warren Company Secretary Little Green Pharma E: <u>a.warren@lgp.global</u> T: +618 6280 0050 David Tasker Managing Director Chapter One Advisors E: <u>dtasker@chapteroneadvisors.com.au</u> T: +61 433 112 936



About Little Green Pharma and Reset Mind Sciences

Little Green Pharma Group is a global, vertically integrated and geographically diverse medicinal cannabis and psychedelics business with operations from cultivation and production through to manufacturing, distribution and clinical services.

The Company has three global production sites for the manufacture of its own-branded and white-label ranges of medicinal cannabis and psychedelic products, being a Danish glasshouse facility and West Australian indoor craft production facility with a combined nameplate capacity of 30 tonnes of cannabis biomass per annum, and a combined psychedelics clinic, head office and therapeutic goods manufacturing facility located in Western Australia.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets and delivers psychedelic assisted psychotherapy services via its wholly-owned Reset Mind Sciences business.

The Company has a strong focus on patient access in global medicinal cannabis markets and the Australian psychedelic market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: <u>www.littlegreenpharma.com</u> and Reset Mind Sciences: <u>https://www.resetmind.com.au/</u>

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

LGP's Cannabis Wrap

LGP's Cannabis Wrap offers insights on global cannabis markets with links to key news and developments from around the world

Sign up to LGP's Cannabis Wrap here: https://investlittlegreenpharma.com/site/contact/newsletter-sign-up